Brief: Paradigm Biopharmaceuticals Says Achieved Primary Endpoint In Para_Oa_008 Phase 2 Clinical Trial
04/10/2022 02:23
Oct 4 (Reuters) - Paradigm Biopharmaceuticals Ltd
PAR.AX :
* ACHIEVES PRIMARY ENDPOINT IN PARA_OA_008 SYNOVIAL FLUID
BIOMARKER PHASE 2 CLINICAL TRIAL
Source text for Eikon: ID:nASXc0pbnw
Further company coverage: PAR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt